GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Eckert & Ziegler Strahlen- und Medizintechnik
Who Owns Eckert & Ziegler Strahlen- und Medizintechnik?
Understanding the ownership of Eckert & Ziegler Strahlen- und Medizintechnik AG is key to grasping its strategic direction. A significant milestone was its 1999 listing on the Frankfurt New Market, which expanded its shareholder base and fueled its growth.
Eckert & Ziegler SE, a global leader in isotope technology, was established in 1992. The company, headquartered in Berlin, Germany, specializes in developing, producing, and distributing radioactive components for various applications, including cancer therapy and nuclear medicine. Their product portfolio includes items like Eckert & Ziegler Strahlen- und Medizintechnik BCG Matrix.
As of July 2025, Eckert & Ziegler holds a market capitalization of approximately $1.62 billion USD. For the 2024 fiscal year, the company reported sales of €295.8 million and an adjusted EBIT of €65.9 million. Projections for 2025 anticipate sales reaching around €320 million.
Who Founded Eckert & Ziegler Strahlen- und Medizintechnik?
The foundation of Eckert & Ziegler Strahlen- und Medizintechnik AG, now Eckert & Ziegler SE, was laid in 1992 by Dr. Andreas Eckert and Jürgen Ziegler. Their initial venture, BEBIG Isotopentechnik und Umweltdiagnostik GmbH, focused on radioactive material recycling, stemming from a research institute. While precise early equity details are scarce, Dr. Andreas Eckert has consistently held a significant ownership percentage, being the largest shareholder with over 30% in 2021 and continuing this position in 2025.
Founding Vision
The company's inception was driven by a vision rooted in isotope technology. This core focus has guided its expansion into critical sectors like cancer therapy and industrial applications.
Evolution of Structure
In 1997, the company transitioned to a holding company structure. This strategic move paved the way for its current corporate form as Eckert & Ziegler Strahlen- und Medizintechnik AG, later evolving into Eckert & Ziegler SE in March 2024.
Early Investment Landscape
Public records do not extensively detail early angel investors or external backers beyond the founders. The company's growth trajectory has been shaped by a combination of internal development and strategic acquisitions.
Core Business Focus
The founding team's expertise in isotope technology remains central to the company's operations. Key areas of concentration include advancements in cancer therapy, industrial radiometry, and nuclear medicine.
Founder's Stake
Dr. Andreas Eckert has historically maintained a substantial ownership interest. As of 2021, his stake exceeded 30%, positioning him as the largest individual shareholder, a status that continued into 2025.
Growth Strategy
The company's expansion has been fueled by both organic growth initiatives and strategic mergers and acquisitions. This dual approach has allowed for continuous development and market penetration.
The initial ownership structure of Eckert & Ziegler Strahlen- und Medizintechnik was primarily driven by its founders, Dr. Andreas Eckert and Jürgen Ziegler. Their entrepreneurial spirit and technical expertise in isotope technology formed the bedrock of the company. Over time, the company's ownership has evolved, reflecting its growth and public market presence. Understanding the Eckert & Ziegler ownership dynamics is crucial for investors and stakeholders interested in the company's trajectory and strategic direction, including insights into its Marketing Strategy of Eckert & Ziegler Strahlen- und Medizintechnik.
Key Ownership Aspects
The ownership of Eckert & Ziegler Strahlen- und Medizintechnik AG, now Eckert & Ziegler SE, is characterized by the significant and consistent stake held by its co-founder, Dr. Andreas Eckert. This founder-led ownership model has been a defining feature since the company's inception in 1992.
- Founders: Dr. Andreas Eckert and Jürgen Ziegler.
- Largest Shareholder: Dr. Andreas Eckert, holding over 30% as of 2021 and continuing in 2025.
- Company Evolution: From BEBIG Isotopentechnik und Umweltdiagnostik GmbH to Eckert & Ziegler Strahlen- und Medizintechnik AG, and then Eckert & Ziegler SE.
- Growth Drivers: Organic expansion and strategic mergers and acquisitions.
- Core Business: Isotope technology for medical and industrial applications, including cancer therapy and nuclear medicine.
Complete Eckert & Ziegler Strahlen- und Medizintechnik Strategy Bundle
- 6 Full Frameworks, 1 Company – All Pre-Researched
- Each Framework Fully Sourced with Real Company Data
- Built for Strategy Courses, Case Studies & MBA Programs
- Adapt to Your Assignment – No Starting from Scratch
- 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's
How Has Eckert & Ziegler Strahlen- und Medizintechnik’s Ownership Changed Over Time?
Eckert & Ziegler SE's ownership journey began with its establishment as a holding company in 1997, evolving significantly with its 1999 IPO on Frankfurt's New Market. This public offering broadened its shareholder base beyond the initial founders, marking a pivotal moment in its corporate history and setting the stage for its current ownership structure.
| Shareholder Type | Stake Percentage (Approx.) | Impact on Company |
|---|---|---|
| Founders/Insiders | 31.13% (Dr. Andreas Eckert) | Significant founder influence and strategic direction. |
| Institutional Investors | Varies (e.g., JPMorgan Asset Management) | Provides capital and professional oversight. |
| Public Float | Remaining percentage | Facilitates market liquidity and price discovery. |
As of July 2025, Eckert & Ziegler SE boasts a market capitalization of approximately $1.62 billion USD. A cornerstone of its ownership structure remains Dr. Andreas Eckert, one of the company's founders, who holds a substantial 31.13% stake, comprising 6,589,964 equities valued at roughly €527 million. This substantial individual holding underscores his continued significant influence. Beyond individual holdings, institutional investors like JPMorgan Asset Management (UK) Ltd. are also key stakeholders, contributing to the company's stability and governance. The company's shares are a component of the TecDAX index on the Deutsche Börse, reflecting its position within the technology sector. The company's financial health, demonstrated by record sales of €295.8 million in 2024 and a forecast of €320 million for 2025, directly impacts investor confidence and the overall Eckert & Ziegler stock ownership landscape. A recent capital increase in July 2025, which raised its share capital to €63,515,796 and included a share split, further aims to enhance liquidity and broaden its investor base, aligning with its strategic objectives for growth and market accessibility. Understanding these dynamics is crucial for comprehending the Growth Strategy of Eckert & Ziegler Strahlen- und Medizintechnik.
Key Eckert & Ziegler Ownership Insights
Eckert & Ziegler's ownership is characterized by a strong founder presence alongside significant institutional investment.
- Dr. Andreas Eckert is the largest individual shareholder with 31.13%.
- Institutional investors like JPMorgan Asset Management are major stakeholders.
- The company's market capitalization was approximately $1.62 billion USD as of July 2025.
- A recent capital increase in July 2025 aimed to boost liquidity and tradability.
From PESTLE Factors to Full Strategy Bundle
- PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
- Every Strategic Angle Covered – Nothing Left to Research
- Pre-filled with Company-Specific Research
- No Missing Sections for Your Case Study
- One Download Covers Your Entire Company Analysis
Who Sits on Eckert & Ziegler Strahlen- und Medizintechnik’s Board?
The Supervisory Board of Eckert & Ziegler SE, as of January 28, 2025, comprises six members who are exclusively shareholder representatives. Dr. Andreas Eckert, the company's founder, chairs this board, holding significant voting power due to his 31.13% shareholding.
| Board Member | Position | Appointment Date | Delegated By |
|---|---|---|---|
| Dr. Andreas Eckert | Chairman of the Supervisory Board | June 7, 2023 | Eckert Wagniskapital und Frühphasenfinanzierung GmbH (EWK) |
| Prof. Dr. Helmut Grothe | Member | 2014 | |
| Albert Rupprecht | Member | 2017 | |
| Dr. Edgar Löffler | Member | 2019 | |
| Paola Eckert-Palvarini | Member | 2023 | |
| Jutta Ludwig | Member | January 1, 2025 | Eckert Wagniskapital und Frühphasenfinanzierung GmbH (EWK) |
The voting power within the company generally follows a one-share-one-vote principle, with 21,171,932 shares of common stock (Stock A) outstanding as of July 25, 2025. The primary shareholder, Eckert Wagniskapital und Frühphasenfinanzierung GmbH (EWK), possesses the non-transferable right to appoint two shareholder representatives to the Supervisory Board, ensuring a concentrated level of control. This structure aligns with legislative values and grants the Supervisory Board significant influence over fundamental decisions and strategic direction. The Executive Board, responsible for daily operations, saw a change effective January 1, 2025, with Dr. Gunnar Mann joining to oversee the Medical segment, while Dr. Harald Hasselmann serves as CEO. The governance environment appears stable, with no significant reported proxy battles or activist investor campaigns, indicating substantial influence from the founding shareholder.
Eckert & Ziegler Strahlen- und Medizintechnik Company Structure
Understanding the ownership and board structure is key to grasping the company's strategic direction. The founder's significant stake and appointment rights highlight a strong influence on governance.
- Founder Dr. Andreas Eckert holds 31.13% of shares.
- EWK has the right to appoint two Supervisory Board members.
- The company operates on a one-share-one-vote principle.
- The Supervisory Board plays a crucial role in strategic decisions.
- Recent changes in the Executive Board include Dr. Gunnar Mann's appointment.
Eckert & Ziegler Strahlen- und Medizintechnik Business Model + Strategy Bundle
- Ideal for Essays, Case Studies & Slides
- Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
- Company-Specific Content Already Organized
- One Bundle Replaces Days of Independent Research
- Buy the Bundle Once. Use Across All Your Assignments
What Recent Changes Have Shaped Eckert & Ziegler Strahlen- und Medizintechnik’s Ownership Landscape?
Eckert & Ziegler Strahlen- und Medizintechnik AG has seen significant shifts in its leadership and capital structure over the past few years, impacting its ownership trends. These changes are designed to foster growth and enhance shareholder value in a dynamic market. The company’s strategic moves reflect a commitment to adapting to industry demands and expanding its global reach.
| Event | Date | Impact |
|---|---|---|
| CEO Transition | June 2023 | Dr. Harald Hasselmann assumed CEO role; Dr. Andreas Eckert became Chairman of the Supervisory Board. |
| Capital Increase | July 2025 | Share capital increased from €21,171,932 to €63,515,796, preceding a share split. |
| Financial Performance (2024) | 2024 | Sales of €295.8 million; Adjusted EBIT of €65.9 million. |
| Financial Outlook (2025) | 2025 | Projected sales of €320 million; Adjusted EBIT of €78 million. |
| Share Price Performance | July 2025 (1-year) | 54% increase; 83% increase over three years. |
Recent developments at Eckert & Ziegler Strahlen- und Medizintechnik AG indicate a strategic evolution in its company structure and ownership outlook. The leadership transition in June 2023, with Dr. Harald Hasselmann taking over as CEO and founder Dr. Andreas Eckert moving to Chairman of the Supervisory Board, signifies a new phase for the company. Dr. Eckert's increased focus on the Pentixapharm spin-off suggests a deliberate unbundling of certain clinical operations, potentially leading to a more streamlined core business. This strategic repositioning, coupled with a substantial capital increase in July 2025 that raised share capital to €63,515,796, is intended to improve share liquidity and attract a broader investor base. These actions, alongside strong financial performance and positive market sentiment, are key factors influencing Eckert & Ziegler ownership trends and its overall company structure.
Leadership Evolution
The transition of leadership in 2023, with Dr. Andreas Eckert stepping down as CEO, marks a significant shift in management. This change is aimed at ensuring continued strategic direction and operational efficiency.
Capital Structure Adjustment
The capital increase in July 2025, raising share capital to over €63 million, is a strategic move to enhance share liquidity. This is a common practice to make the company's stock more accessible to a wider range of Eckert & Ziegler shareholders.
Financial Growth and Outlook
The company reported strong sales of €295.8 million in 2024 and projects continued growth with €320 million in sales for 2025. This financial strength supports investor confidence and can influence Eckert & Ziegler stock ownership patterns.
Market Position and Expansion
Eckert & Ziegler’s active participation in the growing radiopharmaceutical market, including capacity expansions and strategic partnerships, positions it favorably. This growth strategy can attract new investors and impact the Eckert & Ziegler company structure over time, as detailed in a Brief History of Eckert & Ziegler Strahlen- und Medizintechnik.
From Five Forces to Full Company Analysis
- Includes SWOT, PESTLE, BMC, BCG and 4P's
- Pre-Researched with Company-Specific Data
- Best Value for a Complete Analysis
- Ready to Adapt for Your Case Study
- Ready for Essays and Slidesd
- What is Brief History of Eckert & Ziegler Strahlen- und Medizintechnik Company?
- What is Competitive Landscape of Eckert & Ziegler Strahlen- und Medizintechnik Company?
- What is Growth Strategy and Future Prospects of Eckert & Ziegler Strahlen- und Medizintechnik Company?
- How Does Eckert & Ziegler Strahlen- und Medizintechnik Company Work?
- What is Sales and Marketing Strategy of Eckert & Ziegler Strahlen- und Medizintechnik Company?
- What are Mission Vision & Core Values of Eckert & Ziegler Strahlen- und Medizintechnik Company?
- What is Customer Demographics and Target Market of Eckert & Ziegler Strahlen- und Medizintechnik Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.